Cohen Lawrence B Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Cohen Lawrence B decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 29.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,484 shares of the biopharmaceutical company’s stock after selling 2,700 shares during the quarter. Cohen Lawrence B’s holdings in Pfizer were worth $254,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Kanawha Capital Management LLC boosted its stake in Pfizer by 3.0% in the second quarter. Kanawha Capital Management LLC now owns 188,839 shares of the biopharmaceutical company’s stock worth $8,180,000 after buying an additional 5,475 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC boosted its stake in Pfizer by 106.9% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 18,819 shares of the biopharmaceutical company’s stock worth $815,000 after buying an additional 9,725 shares in the last quarter. WealthPLAN Partners LLC boosted its stake in Pfizer by 3.5% in the second quarter. WealthPLAN Partners LLC now owns 80,675 shares of the biopharmaceutical company’s stock worth $2,839,000 after buying an additional 2,708 shares in the last quarter. Winthrop Partners WNY LLC boosted its stake in Pfizer by 6.0% in the second quarter. Winthrop Partners WNY LLC now owns 81,004 shares of the biopharmaceutical company’s stock worth $3,509,000 after buying an additional 4,569 shares in the last quarter. Finally, Barings LLC boosted its stake in Pfizer by 2.3% in the second quarter. Barings LLC now owns 180,786 shares of the biopharmaceutical company’s stock worth $7,832,000 after buying an additional 4,004 shares in the last quarter. 70.19% of the stock is owned by institutional investors and hedge funds.

Shares of PFE stock opened at $40.16 on Tuesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.68 and a current ratio of 0.90. Pfizer Inc. has a fifty-two week low of $33.97 and a fifty-two week high of $44.56. The stock has a 50 day moving average price of $39.37 and a two-hundred day moving average price of $37.97. The company has a market capitalization of $220.37 billion, a P/E ratio of 14.04, a PEG ratio of 4.16 and a beta of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.13. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The firm had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $12.37 billion. During the same quarter in the previous year, the company posted $0.78 earnings per share. The business’s revenue was down 4.6% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 31st will be issued a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.78%. The ex-dividend date is Thursday, January 30th. This is an increase from Pfizer’s previous quarterly dividend of $0.36. Pfizer’s dividend payout ratio is currently 48.00%.

Several brokerages have issued reports on PFE. Credit Suisse Group reaffirmed a “hold” rating and issued a $41.30 target price on shares of Pfizer in a research note on Wednesday, November 6th. Bank of America began coverage on Pfizer in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 target price for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Royal Bank of Canada initiated coverage on Pfizer in a research report on Monday, January 6th. They issued an “outperform” rating and a $46.00 price objective for the company. Nine analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $43.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: Is a Roth IRA right for you?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.